252 related articles for article (PubMed ID: 30904971)
1. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
Rathi E; Kumar A; Kini SG
J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
6. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Konidala KK; Bommu UD; Pabbaraju N
J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
[TBL] [Abstract][Full Text] [Related]
7. Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
Sharma N; Sharma M; Shakeel E; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM; Akhtar S
Med Chem; 2018; 14(6):626-640. PubMed ID: 29663896
[TBL] [Abstract][Full Text] [Related]
8. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
[TBL] [Abstract][Full Text] [Related]
9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
10. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
[TBL] [Abstract][Full Text] [Related]
11. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
[TBL] [Abstract][Full Text] [Related]
12. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
15. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
[TBL] [Abstract][Full Text] [Related]
16. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
17. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
